Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?

Geahča maid

• Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
  Dahkki: Tonkin, A, et al.
  Almmustuhtton: (2006)
• Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
  Dahkki: Colquhoun, D, et al.
  Almmustuhtton: (2004)
• Pravastatin therapy and the risk of stroke.
  Dahkki: White, H, et al.
  Almmustuhtton: (2000)
• Detection of 4a,5-dihydropravastatin as Impurity in the Cholesterol Lowering Drug Pravastatin
  Dahkki: Wibo B. van Scheppingen, et al.
  Almmustuhtton: (2021-08-01)
• Monitoring cholesterol levels: measurement error or true change?
  Dahkki: Glasziou, P, et al.
  Almmustuhtton: (2008)